IL17A and rheumatoid arthritis: For example, a bispecific construct that targets TNF-α and IL-17A has been demonstrated to suppress both TNF-α and IL-17A, resulting in decreased inflammation in animal models, thus supporting its potential role as a therapeutic agent for RA (49).